Table 1 Patient characteristics at diagnosis
| Ā | Combined group | Ā | EBRTā+āBoost | SBRT alone | |
|---|---|---|---|---|---|
Age at diagnosis | Ā | No. patients (%) | P value | No. patients | No. patients |
| Ā | 40-49 | 1 (1.0) | Ā | 0 | 1 |
| Ā | 50-59 | 13 (13.4) | Ā | 9 | 4 |
| Ā | 60-69 | 31 (32.0) | Ā | 12 | 19 |
| Ā | 70-79 | 39 (40.2) | Ā | 20 | 19 |
| Ā | 80-89 | 13 (13.4) | Ā | 4 | 9 |
Mean (range) | Ā | 70.0 (43.2-85.7) | 0.039 | 69.5 (50.6-84.4) | 70.3 (43.2-85.7) |
PSA level at treatment | Ā | ng/mL | Ā | Ā | Ā |
Combined | Mean (range) | 14.4 (0.59-53.1) | Ā | 14.7 | 14.2 |
| Ā | Median | 11.5 | 0.0056 | 12 | 11.25 |
PSA level at diagnosis | Ā | No. patients | Ā | Ā | Ā |
| Ā | <4 ng/mL | 5 (5.2) | Ā | 1 | 4 |
| Ā | 4-10 ng/mL | 30 (30.9) | Ā | 17 | 13 |
| Ā | >10-20 ng/mL | 39 (40.2) | Ā | 16 | 23 |
| Ā | >20 ng/mL | 23 (23.7) | Ā | 11 | 12 |
Clinical stage | Ā | Ā | Ā | Ā | Ā |
| Ā | T1c | 73 (75.2) | 0.22 | 33 | 40 |
| Ā | T2x | 2 (2.1) | Ā | 2 | 0 |
| Ā | T2a | 18 (18.6) | Ā | 6 | 12 |
| Ā | T2b | 2 (2.1) | Ā | 2 | 0 |
| Ā | T2c | 2 (2.1) | Ā | 2 | 0 |
Gleason score | Ā | Ā | 0.55 | Ā | Ā |
| Ā | 6 | 4 (4.1) | Ā | 1 | 3 |
| Ā | 7 (3ā+ā4) | 15 (15.5) | Ā | 7 | 8 |
| Ā | 7 (4ā+ā3) | 16 (16.5) | Ā | 7 | 9 |
| Ā | 8 | 46 (47.4) | Ā | 22 | 24 |
| Ā | 9 | 16 (16.5) | Ā | 8 | 8 |
Hormone treatment | Ā | Ā | 0.34 | Ā | Ā |
| Ā | No | 43 (44.3) | Ā | 17 | 26 |
| Ā | Yes | 54 (55.7) | Ā | 28 | 26 |
RT treatment | Ā | Ā | 0.86 | Ā | Ā |
| Ā | SBRT | 52 (53.6) | Ā | Ā | Ā |
| Ā | EBRTā+āSBRT | 45 (46.4) | Ā | Ā | Ā |
High risk assessment: criteria | Ā | Ā | 0.95 | Ā | Ā |
Gleasonāā„ā8 or PSAā>ā20 | Ā | 83 (85.6) | Ā | 45 | 38 |
Multiple adverse factors*: | Ā | 14 (14.4) | Ā | 0 | 14 |